-
5 Comments
Becton, Dickinson and Company is currently in a long term uptrend where the price is trading 2.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Becton, Dickinson and Company's total revenue rose by 25.8% to $5B since the same quarter in the previous year.
Its net income has increased by 260.8% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 137.9% to $1B since the same quarter in the previous year.
Based on the above factors, Becton, Dickinson and Company gets an overall score of 5/5.
![]() |
TradeWithAlerts
Follow
4 years, 3 months ago
|
![]() |
TradeWithAlerts
Follow
4 years, 3 months ago
|
![]() |
Panna Montana
Follow
4 years, 3 months ago
|
![]() |
TradeWithAlerts
Follow
4 years, 3 months ago
|
Exchange | NYSE |
---|---|
CurrencyCode | USD |
ISIN | US0758871091 |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Market Cap | 59B |
---|---|
PE Ratio | 34.36 |
Target Price | 273.7 |
Dividend Yield | 2.0% |
Beta | 0.38 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BDX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025